Please refer the enclosed the intimation letter
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's Board approved several key items including a final dividend of Rs. 7 per share for FY 2025-26 (total annual dividend Rs. 9.33 per share post-bonus). The company appointed Price Waterhouse Chartered Accountants LLP as new statutory auditors for a 5-year term, replacing M S K A & Associates upon completion of their term. CEO Rahul Franklin Guha was re-appointed for another 5 years (May 2027 to May 2032). Two Non-Executive Non-Independent Directors—Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah—resigned citing preoccupation and other commitments. Two new Additional Directors, Uday Patel Kadam and Gaurav Verma, both from API Holdings (parent company), were appointed. The Board also approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited, a wholly owned subsidiary, and proposed amendments to the Memorandum of Association to expand the company's healthcare and diagnostics business scope.
The resignation of two directors coinciding with appointments from the parent company API Holdings suggests a shift in board composition and potential consolidation of control. Shareholders can expect continued focus on digital transformation and healthcare expansion, supported by the new auditor appointment.